Can adenosine be used safely in pregnancy to treat symptomatic supraventricular tachycardia, and what is the recommended dosing and monitoring?

Adenosine in Pregnancy for Supraventricular Tachycardia

Adenosine is safe and recommended as the first-line pharmacological treatment for acute supraventricular tachycardia in pregnant patients after vagal maneuvers fail, with an initial dose of 6 mg IV rapid bolus, followed by up to two 12 mg doses if needed.

Treatment Algorithm

Step 1: Initial Non-Pharmacological Management

• Attempt vagal maneuvers first (Valsalva, carotid sinus massage, ice-cold towel to face) with patient in supine position 1
• These should be performed quickly as first-line intervention
• Success rate approximately 28% when switching between techniques

Step 2: Adenosine Administration (First-Line Drug)

When vagal maneuvers fail, adenosine is the drug of choice 2, 1

Dosing protocol:

• Initial dose: 6 mg rapid IV bolus
• If ineffective: 12 mg IV bolus (may repeat once)
• Higher doses up to 24 mg have been safely reported 1

Rationale for safety:

• Extremely short half-life prevents drug from reaching fetal circulation 1
• Maternal side effects (chest discomfort, flushing) are transient 1
• Multiple case series demonstrate no adverse fetal effects 3, 4, 5

Step 3: If Adenosine Fails

Second-line options (Class IIa recommendation):

• IV metoprolol or propranolol - reasonable alternative when adenosine ineffective 1
• Use slow infusion to minimize hypotension risk
• Extensive safety data from decades of use in pregnancy

Step 4: Hemodynamic Instability

Synchronized cardioversion if patient is hemodynamically unstable or pharmacological therapy fails 1

• Apply electrode pads directing energy away from uterus
• Perform fetal monitoring during and immediately post-cardioversion if time allows
• Use same energy dosing as non-pregnant patients

Key Safety Considerations

Why adenosine is preferred in pregnancy:

• The 2016 ACC/AHA/HRS guidelines give adenosine a Class I recommendation (highest level) for acute SVT treatment in pregnancy 1
• The 2011 ESC guidelines similarly recommend adenosine as first drug of choice after vagal maneuvers 2
• Published case series show 100% success rate with no maternal or fetal complications 3, 4
• One case documented via ultrasound showed no fetal heart rate changes during maternal adenosine administration 5

Important caveats:

• One 2022 case report suggested possible transient fetal conduction effects (ventricular extrasystole or AV block) 4 seconds after maternal conversion 6, though this remains an isolated observation
• The FDA label states adenosine should be used "only if clearly needed" during pregnancy due to lack of formal reproductive studies 7, but this conservative language conflicts with extensive clinical guideline support
• Do not use in patients with manifest pre-excitation on resting ECG (risk of accelerating ventricular response) 2

Monitoring Requirements

During administration:

• Continuous cardiac monitoring of mother
• Fetal heart rate monitoring when feasible
• Blood pressure monitoring (adenosine causes less hypotension than alternatives like verapamil)

Post-conversion:

• Continue fetal monitoring
• Assess for recurrence (may require prophylactic therapy with digoxin or beta-blockers if recurrent/symptomatic) 2

Clinical Pitfalls to Avoid

1. Don't delay adenosine waiting for "safer" alternatives - it IS the safest option with the most evidence
2. Don't use verapamil first-line - higher hypotension risk than adenosine 1
3. Don't avoid treatment in first trimester - untreated SVT poses greater risk than adenosine exposure
4. Don't use inadequate doses - start with 6 mg but don't hesitate to use 12 mg doses if needed
5. Don't forget rapid bolus technique - slow administration reduces efficacy

The evidence strongly supports adenosine as both safe and effective for maternal SVT throughout all trimesters of pregnancy, with guideline consensus across major cardiology societies.